Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJU 2 Step Haploidentical HSCT for Hematologic Malignancies
NCT01350245Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL) and 7 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Disease-Free Survival at 1 year and Overall Survival at 15 months. Started Jul 2010; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01350245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350245.